Defining Optimal Immunotherapies for Type 1 Diabetes -

Defining Optimal Immunotherapies for Type 1 Diabetes

Buch | Hardcover
222 Seiten
2008
John Wiley & Sons Inc (Verlag)
978-0-470-72325-8 (ISBN)
177,51 inkl. MwSt
* This book is a comprehensive and up-to-date account of where we stand in immunological strategies for preventing or treating type 1 diabetes (T1D).
This book is a comprehensive and up-to-date account of where we stand in immunological strategies for preventing or treating type 1 diabetes (T1D).
Brings together contributions from the leaders in the arena of clinical immunotherapy, not limited to the diabetes field exclusively, in order to delineate a road-map that would lead to future clinical trials.
The book integrates information from human and animal studies.
The book considers T1D within the broader context of autoimmune disease.
The format contains several discussions, which address specific questions and provides guidelines for future strategies and solutions for discovering a cure.

The Novartis Foundation is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.

1. Michael Rutter Introduction: whither gene–environment interactions?

2. Rudolf Uher

Gene–environment interaction: overcoming methodological challenges

Discussion

3. Marco Battaglia, Cecilia Marino, Michel Maziade, Massimo Molteni and Francesca D’Amato

Gene–environment interaction and behavioural disorders: a developmental perspective based on endophenotypes

Discussion

4. Naomi R. Wray, William L. Coventry, Michael R. James, Grant W. Montgomery, Lindon J. Eaves and Nicholas G. Martin

Use of monozygotic twins to investigate the relationship between 5HTTLPR genotype, depression and stressful life events: an application of Item Response Theory

Discussion

Appendix

General discussion I

5. Harold Snieder, Xiaoling Wang, Vasiliki Lagou, Brenda W. J. H. Penninx, Harriëtte Riese and Catharina A. Hartman

Role of gene–stress interactions in gene-finding studies

Discussion

6. Kenneth A. Dodge

Practice and public policy in the era of gene–environment interactions

Discussion

7. Kristi B. Adamo and Frédérique Tesson

Gene–environment interaction and the metabolic syndrome

Discussion

General discussion II

8. Stephen P. Robertson and Richie Poulton

Longitudinal studies of gene–environment interaction in common diseases—good value for money?

Discussion

9. Kee-Seng Chia

Gene–environment interactions in breast cancer

Discussion

10. Malak Kotb, Nourtan Abdeltawab, Ramy Aziz, Sarah Rowe, Robert W. Williams and Lu Lu

Unbiased forward genetics and systems biology approaches to understanding how gene–environment interactions work to predict susceptibility and outcomes of infections

Discussion

11. Steven R. Kleeberger and Hye-Youn Cho

Gene–environment interactions in environmental lung diseases

Discussion

General discussion III

12. Fernando D. Martinez

Gene–environment interaction in complex diseases: asthma as an illustrative case

Discussion

13. Michael Rutter

Conclusions: taking stock and looking ahead

Glossary

Index of contributors

Subject index

Erscheint lt. Verlag 1.12.2008
Reihe/Serie Novartis Foundation Symposium ; Vol.292
Verlagsort New York
Sprache englisch
Maße 158 x 235 mm
Gewicht 476 g
Themenwelt Medizinische Fachgebiete Innere Medizin Diabetologie
Studium Querschnittsbereiche Infektiologie / Immunologie
ISBN-10 0-470-72325-4 / 0470723254
ISBN-13 978-0-470-72325-8 / 9780470723258
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich